Xenothera is a biotech developing new treatments for serious diseases based on a glyco-humanized polyclonal antibody technology.
Xenothera has already introduced four products into the clinic. Two products have reached proof of concept in humans: LIS1 in transplantation, and XAV19 in the treatment of COVID. Two trials are underway in oncology, XON7 in solid tumours (phase I/II FIPO trial) and LIS22 in peripheral T cell lymphoma (phase I/II PALT1 trial). The safety of its technology has now been well documented, with over 400 patients exposed. In oncology, initial clinical data indicate a therapeutic benefit for patients.
Xenothera has its own biomanufacturing site and is supported by the Pays de la Loire region, France 2030 and Europe.